- Previous Close
1.2480 - Open
1.3340 - Bid 1.2580 x --
- Ask 1.2820 x --
- Day's Range
1.2500 - 1.3480 - 52 Week Range
0.8000 - 2.9800 - Volume
57,106 - Avg. Volume
230,588 - Market Cap (intraday)
154.876M - Beta (5Y Monthly) 1.83
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3900 - Earnings Date May 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.50
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
www.kancera.comRecent News: KAN.ST
View More
Performance Overview: KAN.ST
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KAN.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KAN.ST
View MoreValuation Measures
Market Cap
151.24M
Enterprise Value
105.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.28k
Price/Book (mrq)
2.43
Enterprise Value/Revenue
7.54k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.72%
Return on Equity (ttm)
-81.05%
Revenue (ttm)
14k
Net Income Avi to Common (ttm)
-44.57M
Diluted EPS (ttm)
-0.3900
Balance Sheet and Cash Flow
Total Cash (mrq)
46.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-42.82M